Effect of Exenatide on Metabolic and Inflammatory Markers in Diabetic Obese Patients
Abstract
Background: This study aimed to evaluate the effects of exenatide treatment on metabolic and inflammatory markers in patients with type 2 diabetes and obesity.
Methods: This retrospective study included 119 patients diagnosed with type 2 diabetes and obesity who were treated at Dicle University Hospital between July 1, 2013, and December 31, 2019. Patients’ metabolic and inflammatory markers before and after 6 months of exenatide treatment were compared.
Results: The mean age of the patients was 52.26±8.93 years; 17.6% were male, and 82.4% were female. After 6 months of exenatide treatment, significant decreases were observed in the LDH/albumin and CRP/albumin ratios (p<0.05) fasting glucose (160.5 ± 35.2 to 135.8 ± 28.9 mg/dL), HbA1c (8.5 ± 1.2% to 7.2 ± 1.1%), and BMI (34.5 ± 4.2 to 32.8 ± 3.9 kg/m²) (p<0.05). Comorbidities like hypertension and dyslipidemia also showed improvement.
Conclusion: Exenatide treatment demonstrated favorable effects on both metabolic and inflammatory markers in diabetic obese patients. These findings suggest that exenatide may play a beneficial role in the management of chronic inflammation and metabolic control in this patient group.
Keywords
Type 2 diabetes, obesity, exenatide, inflammation, metabolic markers
Ethical Statement
Ethical approval was obtained from the Dicle University Ethics Committee (Approval Number: 2023/296), and the study was conducted in accordance with the Declaration of Helsinki.
References
- World Health Organization. Global report on diabetes. WHO; 2016.
- Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006 Dec 14;444(7121):860-867. doi: 10.1038/nature05485.
- Oral A, Küçük C, Köse M. Real-World Clinical Effectiveness of Liraglutide for Weight Management in Türkiye: Insights from the LIRA-TR Study. Journal of Clinical Medicine. 2024; 13(20):6121. https://doi.org/10.3390/jcm13206121
- Naveirinho J, Pereira JA, Guimarães JT, Carvalho D. GLP-1 receptor agonists and inflammation: a review. Eur J Clin Pharmacol. 2016 Aug;72(8):915-23. doi: 10.1007/s00228-016-2081-1.
- Chan KM, Ladenson JH, Keefe JF. Creatine kinase isoenzyme activities in human serum. Clin Chem. 1978 Apr;24(4):682-685.
- American Diabetes Association. Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023 Jan;46(Supplement_1):S1-S154 . doi: 10.2337/dc23-Sint.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720.
- Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-551. doi: 10.1016/S0140-6736(17)33102-1.